Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flows From Operating Activities:
Net loss	$ (9,321)	$ (25,562)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,008	7,017
Stock-based compensation	3,177	2,462
Accretion of debt discount, recorded to interest expense on 2018 Convertible Notes (Note 14)	1,385	1,270
Amortization of deferred financing costs, recorded to interest expense on 2018 Convertible Notes (Note 14)	171	162
Bad debt (recovery) expense	(16)	44
Impairment of intangible assets (Note 3(f))	0	7,160
Unrealized foreign currency exchange loss	14	1,128
Research and development expense recognized for the value of stock issued in connection with APAZIQUONE milestone (Note 16(b)(ix))	111	0
Change in fair value of contingent consideration related to Talon and EVOMELA acquisitions (Note 9)	1,042	500
Changes in operating assets and liabilities:
Accounts receivable, net	11,186	1,864
Other receivables	(2,500)	(2,399)
Inventories	(2,741)	121
Prepaid expenses	1,154	436
Deferred tax assets	0	(235)
Other assets	(824)	(404)
Accounts payable and other accrued obligations	(9,074)	(2,778)
Accrued payroll and benefits	(3,641)	(4,056)
Drug development liability	(175)	(666)
Deferred revenue	(3,768)	7,555
Deferred tax liability	70	239
Other long-term liabilities	659	855
Net cash used in operating activities	(7,083)	(5,287)
Cash Flows From Investing Activities:
Redemption of mutual funds	(1)	0
Purchase of equity securities (Note 10)	(17)	0
Purchases of property and equipment	(61)	(78)
Net cash used in investing activities	(79)	(78)
Cash Flows From Financing Activities:
Proceeds from exercise of stock options	51	404
Purchase and retirement of restricted stock to satisfy employees' tax liability at vesting	(392)	(262)
Net cash (used in) provided by financing activities	(341)	142
Effect of exchange rates on cash and equivalents	68	(1,354)
Net decrease in cash and cash equivalents	(7,435)	(6,577)
Cash and cash equivalents—beginning of period	139,741	129,942
Cash and cash equivalents—end of period	132,306	123,365
Supplemental disclosure of cash flow information:
Cash paid for income taxes	9	331
Cash paid for interest	$ 0	$ 0